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Summary
Pulmonary hypertension is defined as an increase of 
the mean pulmonary arterial pressure above 25 mm Hg 
and, as such, the diagnosis requires invasive haemo­
dynamic measurement by right heart catheterisation. 
More than just a single disease, pulmonary hyperten­
sion is an umbrella term that includes many different 
disorders and pathophysiological entities. However, 
most forms of pulmonary hypertension share a final 
common pathway, in particular the trias of vasocon­
striction, microthrombosis and vascular remodelling. 
The classification of pulmonary hypertension has been 
subjected to many changes within the last decade. At 
the same time, major achievements in our understand­
ing of the complex pathobiology have been made. Here, 
these developments are discussed in the light of the re­
cently published report from the fifth World Sympo­
sium on pulmonary hypertension.
Definition and haemodynamics
Pulmonary arterial pressure (PAP) is a function of car­
diac output, left atrial pressure and pulmonary vascu­
lar resistance. The pulmonary circulation is a low­pres­
sure system and the mean pulmonary arterial pressure 
(mPAP) does not exceed 20 mm Hg in healthy individ­
uals [1]. Pulmonary hypertension is defined as an in­
crease of the mPAP above 25 mm Hg. Pressure values 
ranging from 21 to 24 mm Hg have been associated 
with a high risk to develop overt pulmonary hyperten­
sion in a subgroup of patients, for example those with 
connective tissue disease [2], but otherwise these pa­
tients are not well defined and not much data exist on 
the prognostic and therapeutic consequences. Use of 
the term “borderline pulmonary 
hypertension” is thus not recom­
mended [3]. Increasing age [4] and 
body weight [5] have been associ­
ated with a rise of systolic pulmo­
nary arterial pressure (sPAP) and 
might explain the gap between nor­
mal mPAP and pulmonary hyper­
tension. 
The presence of pulmonary hypertension might be 
determined by echocardiography, which, depending on 
the underlying cause of elevated pulmonary pressure, 
provides an excellent screening tool. However, sensitiv­
ity and specificity of this method is limited [6]. Diagno­
sis is thus confirmed by invasive haemodynamic as­
sessment with right heart catheterisation at rest. An 
inadequate elevation of pulmonary pressure upon ex­
ercise has been part of former definitions of pulmonary 
hypertension but, due to lack of standardisation, is no 
longer a criterion.
The differentiation of pulmonary hypertension due 
to left heart disease from the other forms is crucial. As 
suggested by guidelines, the pulmonary arterial wedge 
pressure (PAWP, also known as “wedge pressure”) is 
used to estimate left atrial pressure in clinical practice. 
In healthy subjects, PAWP reflects left atrial pressure, 
which is extensively determined by left ventricular 
end­diastolic pressure (LVEDP). Several conditions in­
terfere with this assumption and may lead to misclas­
sification of pulmonary hypertension. Since pulmonary 
vessels are not stiff pipes but rather compressible 
tubes, an increase of the alveolar pressure (e.g., by pul­
monary disease, mechanical ventilation with positive 
end­expiratory pressure) may compress the pulmonary 
capillary bed. This phenomenon, known as the Starling 
resistor model [7], explains the observation of elevated 
PAWP without underlying left­heart disease (left­atrial 
pressure and LVEDP are normal) in the context of pul­
monary diseases. Conversely, PAWP was found to be 
only a moderate discriminator in patients with normal 
or high LVEDP in one recent study [8]. When left heart 
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disease is strongly suspected in the evaluation of pul­
monary hypertension, concomitant measurement of 
LVEPD might be indicated. However, routine assess­
ment of pulmonary hypertension relies on measure­
ment of PAWP.
PAWP values ≤15 mm Hg define precapillary pul­
monary hypertension. PAWP values >15 mm Hg sug­
gest elevations of the pulmonary pressure by hydro­
static back pressure due to left­sided cardiac disorders, 
a condition which is coined postcapillary pulmonary 
hypertension. When the PAWP exceeds 15 mm Hg, the 
difference between diastolic pulmonary arterial pres­
sure (dPAP) and the PAWP further defines the pres­
ence of isolated postcapillary (dPAP­PAWP <7 mm Hg) 
or combined pre­ and postcapillary pulmonary hyper­
tension (dPAP­PAWP ≥7 mm Hg). The use of passive, 
reactive and “out­of­proportion” pulmonary hyperten­
sion has been abandoned in the context of left heart 
disease [9].
Other haemodynamic parameters (table 1) such as 
cardiac output, pulmonary vascular resistance and 
transpulmonary pressure gradient are not required for 
diagnosis but help to identify the pathophysiological 
entities that result in elevated pulmonary pressure. 
Cardiac output is the mathematical product of heart 
rate and stroke volume (and, when further divided by 
body surface area, is referred to as cardiac index).
Pulmonary vascular resistance is calculated by in­
put pressure (i.e., mPAP) minus output pressure (i.e., 
PAWP,) divided by cardiac output (l/min) and is quanti­
fied by Wood units (mm Hg × min/l). Pulmonary vascu­
lar resistance is about 
1
/
10
 of the systemic vascular re­
sistance. Wood units >3 indicate pulmonary hyperten­
sion, and, conversely, patients with values <3 are 
unlikely to have pulmonary hypertension. Pulmonary 
vascular resistance is not a part of the general definition 
of pulmonary hypertension and is not needed for the 
workup of all patients with pulmonary hypertension.
Vasoreactivity testing is mandatory only in the di­
agnostic workup of patients with idiopathic pulmonary 
arterial hypertension but is not recommended in all 
other forms of the disease [3]. Responders to vasoreagi­
bility testing (e.g. NO inhalation) are defined by a de­
crease of the mPAP of more than 10 mm Hg to an abso­
lute value <40 mm Hg without concomitant reduction 
of the cardiac output. Vasoresponders probably reflect 
an early state of the disease in which vasoconstriction 
predominantes. These patients are treated with cal­
cium channel blockers as first line treatment but re­
quire close follow­up since only half of them show long­
term responses [10]. 
Recent studies suggest that occult left heart failure 
is common in patient with pulmonary hypertension [11] 
and misclassification of these patients might result in 
use of “PH­target”­therapies without evidence of benefit. 
The application of a fluid bolus (e.g., 250 or 500 ml sa­
line) during right heart catheterisation to identify these 
patients is not defined and routine application of this 
test cannot be recommended at the moment.
Figure 1 shows the different pressure levels as­
sessed by right heart catheterisation. A modified “diag­
nostic algorithm” is provided in figure 2 [3, 12]. For clin­
Table 1
Common haemodynamic parameters.
Abbreviation Definition Calculation Reference value
CO Cardiac output  4–8 l/min
CI Cardiac index  2.5–4.2 l/min/m
2
mPAP Mean pulmonary artery pressure  9–20 mm Hg
dPAP Diastolic pulmonary artery pressure   
PAWP Pulmonary artery wedge pressure  ≤15 mm Hg
LVEDP Left ventricular end-diastolic pressure  ≤15 mm Hg [12, 68]
TPG Transpulmonary gradient mPAP – PAWP ≤12 mm Hg
DPD Diastolic pressure difference dPAP – PAWP ≤7 mm Hg
PVR Pulmonary vascular resistance 
TPG/CO
80 × TPG/CO
<2 WU (Wood units)
<160 dyn × sec/cm
5
Figure 1
Haemodynamic assessment. Swan-Ganz catheter [63] in situ.  
For details see text.
mPAP = mean pulmonary arterial pressure; PAWP = pulmonary arterial 
wedge pressure; LVEDP = left ventricular enddiastolic pressure. 
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ical practice in cardiology, it is important to distinguish 
pulmonary hypertension due to left heart disease, the 
most common form that causes elevated pulmonary 
pressure, from other forms of pulmonary hypertension.
Classification and epidemiology
Pulmonary hypertension is a big umbrella term that 
summarises several diseases and entities that all re­
sult in elevation of the pulmonary pressure. According 
to a classification system used since 1998, pulmonary 
hypertension can be classified into five entirely differ­
ent clinical and pathophysiological groups (table 2). 
Group 1, which is the main focus of this article, in­
cludes idiopathic and hereditary pulmonary arterial 
hypertension, pulmonary hypertension associated with 
different risk factors and predisposing conditions, pul­
monary veno­occlusive disease, pulmonary capillary 
haemangiomatosis, persistent pulmonary hyperten­
sion of the newborn and congenital heart disease. Only 
group 1 is termed pulmonary arterial hypertension, 
while all the other groups are named pulmonary hyper­
tension. Much confusion is encountered in clinical 
practice with this nomenclature. Group 2 summarises 
pulmonary hypertension due to pathologies of the left 
heart [13, 14], while the pressure elevation in group 3 
is caused by diseases of the lung. These two groups in­
clude the most prevalent aetiologies for pulmonary hy­
pertension, although exact epidemiological data do not 
exist. Group 4 represents pressure elevation due to 
chronic thromboembolic events. Other miscellaneous 
conditions resulting in pulmonary hypertension, such 
as metabolic, haematologic and systemic disorders, are 
subsumed in group 5. The definitions of primary and 
secondary pulmonary hypertension are no longer used. 
With a prevalence of 5–15 cases per million [15], pul­
monary arterial hypertension is considered to be an or­
phan disease. Pulmonary hypertension, however, is a 
very common condition.
The most common causes for group 1 pulmonary 
hypertension include idiopathic and hereditary pulmo­
nary arterial hypertension, pulmonary arterial hyper­
tension in the context of connective tissue disease, con­
genital heart disease, portopulmonary hypertension in 
liver disease, drug­induced pulmonary hypertension, 
and HIV infection (fig. 3) [16]. Exact epidemiological 
data on the incidence of these forms is lacking and vary 
between different registries. The most common forms 
are shortly discussed here, for more details please refer 
to [17]. 
Figure 2
Diagnostic approach to pulmonary hypertension. History and clinical signs 
might suggest the presence of pulmonary hypertension. Step 1: Normal 
levels of NT-proBNP and absence of right heart hypertrophy in ECG have 
been described to have a high sensitivity to exclude pulmonary hyperten-
sion [64]. Echocardiography (TTE) is used as screening tool. mPAP might be 
estimated by adding the right ventricular to right atrial mean systolic 
gradient to right atrial pressure [65] or from the estimated systolic 
pulmonary pressure (right ventricular to right atrial maximal systolic 
gradient + right atrial pressure): mPAP = sPAP × 0.61 + 2 mm Hg [66]. 
When pulmonary hypertension is suggested by these screening tools, 
underlying heart disease (step 2) and chronic lung disorders (step 3) have 
to be excluded (RX = chest radiography; PFT = pulmonary function testing 
incl. diffusion capacity for carbon monoxide); BGA = blood gas analysis; 
HRCT = high-resolution computed tomography). In the absence of such 
conditions, chronic thromboembolic pulmonary hypertension is investi-
gated by ventilation/perfusion scintigraphic or MR angiography [67]  
(step 4). Diagnosis of pulmonary hypertension is confirmed by right heart 
catheterisation and can further be classified in pre- and postcapillary 
elevation of pulmonary pressure. According to the levels of the diastolic 
pressure difference (DPD), postcapillary pulmonary hypertension is isolated 
or combined with precapillary pressure elevation (step 5).
Table 2
Classification of pulmonary hypertension (simplified).
1. Pulmonary arterial hypertension
     1.1 Idiopathic PAH
     1.2 Heritable PAH
     1.3 Drug- and toxin-induced
     1.4  Associated with connective tissue disease, HIV infection, 
portal hypertension, congenital heart diseases,  
schistosomiasis
2. Pulmonary hypertension due to left heart disease
3. Pulmonary hypertension due to lung diseases and/or hypoxia
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5.  Pulmonary hypertension with unclear multifactorial  
mechanisms
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Hereditary pulmonary arterial hypertension
The most common mutations in pulmonary arterial hy­
pertension are loss­of­function mutations in the gene 
encoding for the bone morphogenetic protein receptor 
type II (BMPR2, see below), which is located on the 
long arm of chromosome 2 (2q33). Since the initial re­
port on BMPR2 mutation [18] more than 300 other ge­
netic variants have been identified in the context of 
pulmonary hypertension. These mutations can be 
found in about 70% of familial and in up to 30% of idio­
pathic forms of pulmonary arterial hypertension. These 
forms are thus summarised as hereditary pulmonary 
arterial hypertension. While several other mutations of 
downstream factors of BMPR2, coreceptors and other 
mediators have been described, changes in the expres­
sion of BMPR2 remain the ones with the most impor­
tance for prevalence and pathogenesis. Screening for 
such mutations is not recommended routinely and, in 
our centre, is rarely performed. 
Connective tissue disease
Pulmonary hypertension is a comorbidity that can be 
found in all connective tissue diseases, including sys­
temic sclerosis, systemic lupus erythematosus, poly­
myo sitis/dermatomyositis (antisynthetase syndrome) 
[19] and rheumatoid arthritis. Epidemiological studies 
suggest that pulmonary hypertension is a common 
finding in patients with systemic sclerosis (more than 
10% of patients [20]). However, pulmonary hyperten­
sion in systemic sclerosis is complicated by the fact 
that elevation of pulmonary pressure can also be 
caused – or at least be aggravated – by parenchymal 
lung disease and left heart failure making it very diffi­
cult to identify the causative factor that results in ele­
vated pulmonary pressure [21]. Additional vasodilata­
tion of the pulmonary circulation may aggravate left 
heart failure and explain why patients with pulmonary 
hypertension associated with systemic sclerosis have a 
worse outcome when treated with PH­target therapies 
compared to those with pulmonary arterial hyperten­
sion due to other aetiologies [22]. Patients with connec­
tive tissue disease should be screened with annual 
echocardiography or when developing symptoms.
Congenital heart disease / GUCH  
(grown-up congenital heart disease)
The prevalence of pulmonary arterial hypertension in 
adults with congenital heart defects (CHD) is not well 
defined. It is strongly influenced by the type of defect, 
and type and timing of surgical repair. Chronic expo­
sure of the pulmonary vascular bed to volume overload 
secondary to chronic high output and in particular to 
pressure overload (e.g. through ventricular or arterial 
shunts), may result in obstructive arteriopathy of pul­
monary vessels. The extreme form of pulmonary arte­
rial hypertension associated with CHD is Eisen­
menger’s syndrome, where PVR equalises or exceeds 
systemic vascular resistance resulting in cyanosis and 
clubbing through bidirectional or reversal shunting 
[23]. In industrialised countries congenital heart de­
fects are usually diagnosed early in life and timely sur­
gical repair prevents development of pulmonary arte­
rial hypertension in most cases. As a result, the cohort 
of Eisenmenger patients is slowly decreasing in these 
countries. In developing countries Eisenmenger’s syn­
drome is still prevalent.
With modern heart surgery and cardiology care 
most patients with congenital heart disease now sur­
vive to adulthood, even those with complex lesions [24]. 
These adults are not cured. Some of these complex pa­
tients (i.e., Fontan circulation for single­ventricle phys­
iology) may develop pulmonary vascular disease in 
long­term follow­up with adverse outcome [25]. Other 
types of pulmonary hypertension observed in the con­
text of CHD (e.g., congenital cardiomyopathies, inflow 
/ outflow obstructions) belong to group 2.
Portopulmonary hypertension
Pulmonary arterial hypertension is present in 5–10% 
of patients with cirrhotic liver disease [26]. The exact 
pathogenetic mechanisms underlying elevation of pul­
monary pressure are not completely clear. Incomplete 
clearance of vasoconstrictive mediators by the diseased 
Figure 3
Epidemiology of pulmonary hypertension. Schematic representation of 
the 5 pulmonary hypertension groups (grey circles). The most prevalent 
aetiologies of pulmonary hypertension are group 2 (left heart diseases, 
PH-LHD) and group 3 (lung diseases, PH-LUNG). Group 1 (pulmonary 
arterial hypertension, PAH) is an orphan disease with different causes 
(prevalence according to [16]). The prevalence of chronic thromboem-
bolic pulmonary hypertension (CETPH) and of pulmonary hypertension 
due to miscellaneous aetiologies (PH-misc) is unknown.
PH-LHD
PH-LUNG
CTEPH
PH-misc
hereditary/
idiopathic
CTD
PPHTN
HIV
congenital drugs
CTD = connective tissue disease 
PPHTN = portopulmonary hypertension
45%
16%
1
1
%
6%
12%
10%
PAH
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liver and increase in inflammatory cytokines such as 
Interleukin­6 [27] might play a major role. Of interest, 
onset and prevalence of pulmonary hypertension is not 
related to the severity of liver disease and can be ob­
served at any stage of the Child­Pugh classification. 
Portopulmonary hypertension is more common in fe­
male patients and in autoimmune hepatitis, whereas 
male gender and hepatitis C infection appear to be pro­
tective factors [28]. The therapy of co­existing liver and 
pulmonary hypertensive disease is a challenge particu­
larly because betablockers applied to reduce portal 
pressure and prevent variceal bleeding should not be 
used in pulmonary hypertension. In addition oral anti­
coagulation is contraindicated in liver disease because 
of the risk of coagulopathies. Finally, PH target thera­
pies might be hepatotoxic and orthotopic liver trans­
plantation is difficult to perform in the presence of pul­
monary hypertension.
Drugs and toxins
Several drugs and toxins have been investigated for an 
association with the development of pulmonary arte­
rial hypertension. A causative role has been proposed 
for several anorexigens including a recent report on 
Benfluorex in France [29], and selective serotonine re­
uptake inhibitors in pregnant women that result in 
pulmonary arterial hypertension of the newborns. Il­
licit drugs such as cocaine and amphethamine­like 
drugs show a possible association. The tyrosine kinase 
inhibitor dasatinib has recently been associated with 
pulmonary hypertension [30] and, following initial 
 enthusiasm in case reports [31, 32] the use of tyrosine 
 kinase inhibitors for pulmonary hypertension is now 
questioned [33]. An association is less likely for oral 
contraceptives and oestrogens. The role of smoking is 
controversial but prevalence of smoking appears to be 
higher in patients with pulmonary arterial hyperten­
sion [34]. In addition, smoking is associated with in­
creased vascular remodelling in pulmonary arteries 
[35] and significant reduction of diffusion capacity [36].
Human immunodeficiency virus
HIV patients have an increased prevalence for pulmo­
nary arterial hypertension [37]. Current epidemiologi­
cal data suggest that about 0.5% of HIV patients de­
velop elevated pulmonary arterial pressure. The patho­
genesis of HIV­associated pulmonary hypertension is 
unclear, but chronic inflammation is thought to be of 
importance. The interesting data on the causative role 
of human herpesvirus­8 [38] (which is responsible for 
the development of Kaposi Sarcoma and lymphoprolif­
erative Castleman’s disease) have not been confirmed. 
Whether antiretroviral treatment might also reduce 
pulmonary arterial pressure remains controversial but 
it has been shown that prolonged treatment of subjects 
with HIV­related pulmonary hypertension results in 
normalisation of elevated pulmonary pressure in about 
one third of patients and is associated with reduced 
mortality [39].
Pathobiology
In the update from Nice 2013 on the clinical classifica­
tion of pulmonary hypertension almost 30 entities are 
listed as different aetiologies for pulmonary hyperten­
sion. Of interest, most of these forms result in the small 
pulmonary arteries (<300 μm) in a final common path­
way of vasoconstriction, microthrombosis and vascular 
remodelling (fig. 4). This makes it impossible to distin­
guish different aetiologies in established disease by, for 
example, pathomorphology of pulmonary vessels.
Vasoconstriction
Vasoconstriction without microthrombosis and vascu­
lar remodelling possibly reflects an early and probably 
reversible stage of disease. Contraction of vascular 
smooth muscle cells, mainly mediated by excessive re­
lease of intracellular calcium [40], is due to a dysbal­
ance of vasoactive factors. For example, elevated levels 
of endothelin­1, one of the strongest vasoconstrictors, 
detected in the circulation of patients with pulmonary 
arterial hypertension, correlate positively with haemo­
dynamic parameters such as mPAP [41]. Conversely, 
the production of the vasorelaxative factor nitric oxide 
and its second messenger cyclic guanosine monophos­
phate (cGMP) are reduced in patients with pulmonary 
arterial hypertension [42]. Similarly, relaxative prosta­
cyclins and cyclic adenosine monophosphate are re­
duced in vessels of patients with pulmonary arterial 
hypertension [43]. Most currently used PH­target ther­
apies are specific vasodilators that interact with one of 
these systems. In addition, cardiopulmonary reflexes 
might trigger or – by a vicious cycle of hypoxia and va­
soconstriction – aggravate the constriction of pulmo­
nary arteries. The most important reflex in this context 
Figure 4
Pathogenetic factors in pulmonary hypertension. Most aetiologies 
identified in pulmonary hypertension result in a final common pathway 
with vasoconstriction, microthrombosis and vascular remodelling.
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is the Euler­Liljestrand reflex, which describes a para­
doxical response of pulmonary artery smooth muscle 
cells to hypoxia and which minimises ventilation / per­
fusion mismatch in the lung by directing blood flow to 
ventilated areas. The Hermo­Weiler (or Kitaev)­reflex 
is important for the development of pulmonary hyper­
tension in left heart disease and describes vasocon­
striction of precapillary pulmonary arteries upon pres­
sure increase of the left atrium (reviewed in [44]).
Microthrombosis
It is well known that in situ thrombotic events within 
small pulmonary arteries are common in patients with 
pulmonary arterial hypertension and occur more fre­
quently with longer duration of the disease and in­
creasing age of the patient. Several abnormalities in 
the coagulation system have been described including 
reduced anticoagulatory activity of protein C and S, in­
creased activity of von Willebrand factor and reduced 
fibrinolysis by increased expression of the plasminogen 
activator inhibitor [45–47]. The increased coagulability 
with thrombosis contributes to the pathobiologic evolu­
tion of the disease and justifies the use of oral antico­
agulation in patients with pulmonary arterial hyper­
tension [48].
Vascular remodelling
Vascular remodelling is arguably the most important 
pathogenetic event in the development of pulmonary 
arterial hypertension. In contrast to vasoconstriction 
and microthrombosis which can be treated successfully, 
vascular remodelling of small pulmonary arteries is 
recognised as the main cause of the chronicity and pro­
gression of pulmonary hypertension and explains the 
refractoriness of the disease to current therapeutic reg­
imens. This remodelling is characterised by an exces­
sive proliferation of vascular smooth muscle cells and 
the formation of a neointimal layer, which result in in­
creased thickness of the pulmonary arterial vessel wall 
and occlusion of the vascular lumen [49, 50]. With the 
exception of plexiform lesions, which are focal prolifer­
ations of endothelial channels lined by myofibroblasts 
[51] and a characteristic feature of group 1 pulmonary 
arterial hypertension, the pattern of vascular remodel­
ling is indistinguishable between the different aetiolo­
gies of elevated pulmonary pressure [52]. A character­
istic example of vascular remodelling in pulmonary 
 hypertension is provided in figure 5.
Despite many advances, the pathogenesis of the 
vascular remodelling is still a matter of debate. It has 
been demonstrated that a complex network of different 
factors, including growth factors, neurohumoral trans­
mitters, infections, inflammatory cells, cytokines, 
chemokines and voltage­gated potassium channels, 
contribute to the remodelling process. A major role in 
triggering vascular remodelling has been attributed to 
the bone morphogenetic protein receptor type II 
(BMPR2). The BMPR2 is a member of a family of 
growth factor receptors (transforming growth factor 
beta receptors) and located at the surface of endothelial 
and vascular smooth muscle cells. Mutations in the 
BMPR2 result in increased cell survival and prolifera­
tion, and have been identified as causative factors in 
the development of hereditary pulmonary arterial hy­
pertension. The fact that BMPR2 mutations can be 
found in up to 70% of families with pulmonary hyper­
tension and in up to one third of patients with idio­
pathic pulmonary arterial hypertension indicate that 
additional factors are responsible for the development 
and progression of pulmonary hypertension. In recent 
years, it has become clear that in many nongenetic 
forms of pulmonary hypertension – such as congenital 
heart disease [53, 54], HIV­infection [55], left heart dis­
ease [54] and chronic hypoxia including the major ex­
perimental models of the disease [56, 57] – the BMPR2 
is downregulated and its signalling pathways are dys­
functional. This downregulation might be due to the 
 action of microRNAs (i.e., small noncoding RNA frag­
ments) that bind to the mRNA of the BMPR2 and in­
hibit its translation [58]. The use of BMPR2 transfection 
in case of genetic mutations or the application of antag­
omiRs that inhibit microRNAs specifically in nonge­
netic forms of the disease have been shown to prevent 
Figure 5
Remodelling. Various vascular abnormalities in a patient with idiopathic 
pulmonary arterial hypertension.
A Pulmonary artery with media hypertrophy.
B  Artery with extensive intima fibrosis, subtotal luminal occlusion 
and recanalisation. 
C, D  Plexiform lesions (EvG-staining) adjacent to a feeding artery 
with intimal fibrosis, media hypertrophy (C) and collection  
of convoluted, dilated thin-walled vessel segments simulating a 
haemangioma (D).
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or treat vascular remodelling and improve haemody­
namics in experimental models of the disease [59–62]. 
Whether such an approach for a “reverse remodelling” 
is feasible and successful in human disease remains to 
be elucidated.
Acknowledgement
We would like to thank PD Dr Matthias Greutmann 
(Head Congenital Heart Disease, University Hospital 
Zurich) for helpful comments on GUCH patients with 
pulmonary arterial hypertension.
References
 1 Wilkins LW, West JB. Respiratory Physiology. 2012. 
 2 Bae S, Saggar R, Bolster MB, Chung L, Csuka ME, Derk C, et al. Base­
line characteristics and follow­up in patients with normal haemody­
namics versus borderline mean pulmonary arterial pressure in systemic 
sclerosis: results from the PHAROS registry. Ann Rheum Dis. 2012; 
71(8):1335–42. 
 3 Hoeper MM, Bogaard HJ, Condliffe R, Frantz R, Khanna D, Kurzyna 
M, et al. Definitions and diagnosis of pulmonary hypertension. J Am 
Coll Cardiol. 2013;62(25 Suppl):D42–50. 
 4 Lam CSP, Borlaug BA, Kane GC, Enders FT, Rodeheffer RJ, Redfield 
MM. Age­associated increases in pulmonary artery systolic pressure in 
the general population. Circulation. Lippincott Williams & Wilkins; 
2009;119(20):2663–70. 
 5 McQuillan BM, Picard MH, Leavitt M, Weyman AE. Clinical Correlates 
and Reference Intervals for Pulmonary Artery Systolic Pressure Among 
Echocardiographically Normal Subjects. Circulation. 2001;104(23): 
2797–802. 
 6 Janda S, Shahidi N, Gin K, Swiston J. Diagnostic accuracy of echocar­
diography for pulmonary hypertension: a systematic review and me­
ta­analysis. Heart. 2011;97(8):612–22. 
 7 Knowlton FP, Starling EH. The influence of variations in temperature 
and blood­pressure on the performance of the isolated mammalian 
heart. J Physiol. 1912;44(3):206–19. 
 8 Halpern SD. Misclassification of Pulmonary Hypertension Due to Re­
liance on Pulmonary Capillary Wedge Pressure Rather Than Left Ven­
tricular End­Diastolic Pressure. Chest. 2009;136(1):37. 
 9 Vachiéry J­L, Adir Y, Barberà JA, Champion H, Coghlan JG, Cottin V, 
et al. Pulmonary hypertension due to left heart diseases. J Am Coll Car­
diol. 2013;62(25 Suppl):D100–8. 
10 Sitbon O. Long­Term Response to Calcium Channel Blockers in Idio­
pathic Pulmonary Arterial Hypertension. Circulation. 2005;111(23): 
3105–11. 
11 Robbins IM, Hemnes AR, Pugh ME, Brittain E, Zhao DX, Piana RN, et 
al. High Prevalence of Occult Pulmonary Venous Hypertension Re­
vealed by Fluid Challenge in Pulmonary Hypertension. Circulation: 
Heart Failure. 2013 Dec 2. 
12 Authors/Task Force Members, Galie N, Hoeper MM, Humbert M, Tor­
bicki A, Vachiery JL, et al. Guidelines for the diagnosis and treatment 
of pulmonary hypertension: The Task Force for the Diagnosis and Treat­
ment of Pulmonary Hypertension of the European Society of Cardiol­
ogy (ESC) and the European Respiratory Society (ERS), endorsed by 
the International Society of Heart and Lung Transplantation (ISHLT). 
Eur Heart J. 2009;30(20):2493–537. 
13 Hansdottir S, Groskreutz DJ, Gehlbach BK. WHO’s in Second? Chest. 
2013;144(2):638. 
14 Arrigo M, Huber LC. Passive Pulmonary Hypertension. Chest. 
2014;145(2):413. 
15 Ling Y, Johnson MK, Kiely DG, Condliffe R, Elliot CA, Gibbs JSR, et al. 
Changing Demographics, Epidemiology, and Survival of Incident Pul­
monary Arterial Hypertension. Am J Respir Crit Care Med. 2012; 
186(8):790–6. 
16 Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et 
al. Pulmonary Arterial Hypertension in France. Am J Respir Crit Care 
Med. 2006;173(9):1023–30. 
17 Simonneau G, Gatzoulis MA, Adatia I, Celermajer D, Denton C, Ghof­
rani A, et al. Updated clinical classification of pulmonary hypertension. 
J Am Coll Cardiol. 2013;62(25 Suppl):D34–41. 
18 International PPH Consortium, Lane KB, Machado RD, Pauciulo MW, 
Thomson JR, Phillips JA, et al. Heterozygous germline mutations in 
BMPR2, encoding a TGF­beta receptor, cause familial primary pulmo­
nary hypertension. Nat Genet. 2000;26(1):81–4. 
19 Hervier B, Meyer A, Dieval C, Uzunhan Y, Devilliers H, Launay D, et 
al. Pulmonary hypertension in antisynthetase syndrome: prevalence, 
aetiology and survival. Eur Respir J. 2013;42(5):1271–82. 
20 Mukerjee D, St George D, Coleiro B, Knight C, Denton CP, Davar J, et 
al. Prevalence and outcome in systemic sclerosis associated pulmonary 
arterial hypertension: application of a registry approach. Ann Rheum 
Dis. 2003;62(11):1088–93. 
21 Coghlan G. Does left heart disease cause most systemic sclerosis asso­
ciated pulmonary hypertension? Eur Respir J. 2013;42(4):888–90. 
22 Fox BD, Shimony A, Langleben D, Hirsch A, Rudski L, Schlesinger R, 
et al. High prevalence of occult left heart disease in scleroderma­pul­
monary hypertension. Eur Respir J. 2013;42(4):1083–91. 
23 WOOD P. The Eisenmenger syndrome or pulmonary hypertension with 
reversed central shunt. I. Br Med J. 1958;2(5098):701–9. 
24 Marelli AJ, Mackie AS, Ionescu­Ittu R, Rahme E, Pilote L. Congenital 
Heart Disease in the General Population: Changing Prevalence and Age 
Distribution. Circulation. 2006;115(2):163–72. 
25 Beghetti M. Fontan and the pulmonary circulation: a potential role for 
new pulmonary hypertension therapies. Heart. BMJ Publishing Group 
Ltd and British Cardiovascular Society; 2010;96(12):911–6. 
26 Hervé P, Lebrec D, Brenot F, Simonneau G, Humbert M, Sitbon O, et al. 
Pulmonary vascular disorders in portal hypertension. Eur Respir J. 
1998;11(5):1153–66. 
27 Pellicelli AM, Barbaro G, Puoti C, Guarascio P, Lusi EA, Bellis L, et al. 
Plasma Cytokines and Portopulmonary Hypertension in Patients With 
Cirrhosis Waiting for Orthotopic Liver Transplantation. Angiology. 
2010;61(8):802–6. 
28 Kawut SM, Krowka MJ, Trotter JF, Roberts KE, Benza RL, Badesch 
DB, et al. Clinical risk factors for portopulmonary hypertension. Hepa­
tology. 2008;48(1):196–203. 
29 Savale L, Chaumais MC, Cottin V, Bergot E, Frachon I, Prevot G, et al. 
Pulmonary hypertension associated with benfluorex exposure. Euro­
pean Respiratory Journal. European Respiratory Society; 2012;40(5): 
1164–72. 
30 Montani D, Bergot E, Gunther S, Savale L, Bergeron A, Bourdin A, et 
al. Pulmonary Arterial Hypertension in Patients Treated by Dasatinib. 
Circulation. 2012;125(17):2128–37. 
31 Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of 
pulmonary arterial hypertension. N Engl J Med. 2005;353(13):1412–3. 
32 Speich R, Treder U, Domenighetti G, Huber LC, Ulrich S. Weaning from 
intravenous prostanoids and normalization of hemodynamics by long­
term imatinib therapy in severe idiopathic pulmonary arterial hyper­
tension. Int J Clin Pharm. 2013 Nov 28. 
33 Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galie N, et al. 
Imatinib Mesylate as Add­on Therapy for Pulmonary Arterial Hyper­
tension: Results of the Randomized IMPRES Study. Circulation. 
2013;127(10):1128–38. 
34 Schiess R. Tobacco Smoke: A Risk Factor for Pulmonary Arterial Hy­
pertension? Chest. 2010;138(5):1086. 
35 Santos S, Peinado VI, Ramirez J, Melgosa T, Roca J, Rodriguez­Roisin 
R, et al. Characterization of pulmonary vascular remodelling in smok­
ers and patients with mild COPD. Eur Respir J. 2002;19(4):632–8. 
36 Trip P, Nossent EJ, de Man FS, van den Berk IAH, Boonstra A, Groepen­
hoff H, et al. Severely reduced diffusion capacity in idiopathic pulmo­
nary arterial hypertension: patient characteristics and treatment re­
sponses. Eur Respir J. 2013;42(6):1575–85. 
37 Speich R. Primary pulmonary hypertension in HIV infection. Chest. 
1991;100(5):1268. 
38 Cool CD, Rai PR, Yeager ME, Hernandez­Saavedra D, Serls AE, Bull 
TM, et al. Expression of human herpesvirus 8 in primary pulmonary 
hypertension. N Engl J Med. 2003;349(12):1113–22. 
39 Zuber J­P, Calmy A, Evison JM, Hasse B, Schiffer V, Wagels T, et al. Pul­
monary arterial hypertension related to HIV infection: improved hemo­
dynamics and survival associated with antiretroviral therapy. Clin In­
fect Dis. Oxford University Press; 2004;38(8):1178–85. 
40 Sommer N, Dietrich A, Schermuly RT, Ghofrani HA, Gudermann T, 
Schulz R, et al. Regulation of hypoxic pulmonary vasoconstriction: ba­
sic mechanisms. Eur Respir J. 2008;32(6):1639–51. 
41 Rubens C, Ewert R, Halank M, Wensel R, Orzechowski HD, Schulthe­
iss HP, et al. Big endothelin­1 and endothelin­1 plasma levels are cor­
related with the severity of primary pulmonary hypertension. Chest. 
2001;120(5):1562–9. 
Cardiovascular Medicine 2014;17(11):312–319 319
REVIEW ARTICLE
42 Giaid A, Saleh D. Reduced expression of endothelial nitric oxide syn­
thase in the lungs of patients with pulmonary hypertension. N Engl J 
Med. 1995;333(4):214–21. 
43 Tuder RM, Cool CD, Geraci MW, Wang J, Abman SH, Wright L, et al. 
Prostacyclin synthase expression is decreased in lungs from patients 
with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999; 
159(6):1925–32. 
44 Arrigo M, Huber LC. Eponyms in cardiopulmonary reflexes. Am J Car­
diol. Elsevier; 2013;112(3):449–53. 
45 Wagenvoort CA, Mulder PG. Thrombotic lesions in primary plexogenic 
arteriopathy. Similar pathogenesis or complication? Chest. 1993;103(3): 
844–9. 
46 Welsh CH, Hassell KL, Badesch DB, Kressin DC, Marlar RA. Coagula­
tion and fibrinolytic profiles in patients with severe pulmonary hyper­
tension. Chest. 1996;110(3):710–7. 
47 Hoeper MM, Sosada M, Fabel H. Plasma coagulation profiles in patients 
with severe primary pulmonary hypertension. Eur Respir J. 1998;12(6): 
1446–9. 
48 Johnson SR, Granton JT, Tomlinson GA, Grosbein HA, Hawker GA, 
Feldman BM. Effect of warfarin on survival in scleroderma­associated 
pulmonary arterial hypertension (SSc­PAH) and idiopathic PAH. Belief 
elicitation for Bayesian priors. J Rheumatol. The Journal of Rheuma­
tology; 2011;38(3):462–9. 
49 Dorfmuller P, Humbert M. Progress in pulmonary arterial hyperten­
sion pathology: relighting a torch inside the tunnel. Am J Respir Crit 
Care Med. 2012;186(3):210–2. 
50 Guignabert C, Dorfmuller P. Pathology and Pathobiology of Pulmonary 
Hypertension. Semin Respir Crit Care Med. 2013;34(05):551–9. 
51 Pietra GG, Capron F, Stewart S, Leone O, Humbert M, Robbins IM, et 
al. Pathologic assessment of vasculopathies in pulmonary hypertension. 
J Am Coll Cardiol. 2004;43(12):S25–S32. 
52 Dorfmüller P, Humbert M, Capron F. Update on the pathomorphologi­
cal assessment of vasculopathies in pulmonary arterial hypertension. 
Pathologe. 2006;27(2):140–6. 
53 Atkinson C. Primary Pulmonary Hypertension Is Associated With Re­
duced Pulmonary Vascular Expression of Type II Bone Morphogenetic 
Protein Receptor. Circulation. 2002;105(14):1672–8. 
54 MD HI, MD SK, PhD KTM, PhD KOM. Attenuation of bone morphoge­
netic protein receptor type 2 expression in the pulmonary arteries of 
patients with failed Fontan circulation. The Journal of Thoracic and 
Cardiovascular Surgery. The American Association for Thoracic Sur­
gery; 2012;143(4):e24–6. 
55 Dalvi P, O’Brien­Ladner A, Dhillon NK. Downregulation of Bone Mor­
phogenetic Protein Receptor Axis During HIV­1 and Cocaine­Mediated 
Pulmonary Smooth Muscle Hyperplasia: Implications for HIV­Related 
Pulmonary Arterial Hypertension. Arterioscler Thromb Vasc Biol. 
2013;33(11):2585–95. 
56 Takahashi H. Downregulation of type II bone morphogenetic protein 
receptor in hypoxic pulmonary hypertension. AJP: Lung Cellular and 
Molecular Physiology. 2005;290(3):L450–8. 
57 Morty RE, Nejman B, Kwapiszewska G, Hecker M, Zakrzewicz A, Kouri 
FM, et al. Dysregulated Bone Morphogenetic Protein Signaling in Mono­
crotaline­Induced Pulmonary Arterial Hypertension. Arterioscler 
Thromb Vasc Biol. 2007;27(5):1072–8. 
58 Brock M, Trenkmann M, Gay RE, Michel BA, Gay S, Fischler M, et al. 
Interleukin­6 Modulates the Expression of the Bone Morphogenic Pro­
tein Receptor Type II Through a Novel STAT3–microRNA Cluster 17/92 
Pathway. Circ Res. 2009;104(10):1184–91. 
59 Reynolds AM, Xia W, Holmes MD, Hodge SJ, Danilov S, Curiel DT, et 
al. Bone morphogenetic protein type 2 receptor gene therapy attenu­
ates hypoxic pulmonary hypertension. AJP: Lung Cellular and Molec­
ular Physiology. 2007;292(5):L1182–92. 
60 Reynolds AM, Holmes MD, Danilov SM, Reynolds PN. Targeted gene 
delivery of BMPR2 attenuates pulmonary hypertension. Eur Respir J. 
2012;39(2):329–43. 
61 Pullamsetti SS, Doebele C, Fischer A, Savai R, Kojonazarov B, Dahal 
BK, et al. Inhibition of MicroRNA­17 Improves Lung and Heart Func­
tion in Experimental Pulmonary Hypertension. Am J Respir Crit Care 
Med. 2012;185(4):409–19. 
62 Brock M, Samillan VJ, Trenkmann M, Schwarzwald C, Ulrich S, Gay 
RE, et al. AntagomiR directed against miR­20a restores functional 
BMPR2 signalling and prevents vascular remodelling in hypoxia­in­
duced pulmonary hypertension. Eur Heart J. 2012 Mar 26. 
63 Swan HJ, Ganz W, Forrester J, Marcus H, Diamond G, Chonette D. Cath­
eterization of the heart in man with use of a flow­directed balloon­tipped 
catheter. N Engl J Med. 1970;283(9):447–51. 
64 Bonderman D, Wexberg P, Martischnig AM, Heinzl H, Lang MB, Sadu­
shi R, et al. A noninvasive algorithm to exclude pre­capillary pulmo­
nary hypertension. Eur Respir J. 2011;37(5):1096–103. 
65 Aduen JF, Castello R, Lozano MM, Hepler GN, Keller CA, Alvarez F, 
et al. An Alternative Echocardiographic Method to Estimate Mean Pul­
monary Artery Pressure: Diagnostic and Clinical Implications. Journal 
of the American Society of Echocardiography. Elsevier; 2009;22(7): 
814–9. 
66 Chemla D. New Formula for Predicting Mean Pulmonary Artery Pres­
sure Using Systolic Pulmonary Artery Pressure. Chest. 2004;126(4): 
1313–7. 
67 Rajaram S, Swift AJ, Telfer A, Hurdman J, Marshall H, Lorenz E, et al. 
3D contrast­enhanced lung perfusion MRI is an effective screening tool 
for chronic thromboembolic pulmonary hypertension: results from the 
ASPIRE Registry. Thorax. BMJ Publishing Group Ltd and British Tho­
racic Society; 2013;68(7):677–8. 
68 Paulus WJ, Tschope C, Sanderson JE, Rusconi C, Flachskampf FA, Rade­
makers FE, et al. How to diagnose diastolic heart failure: a consensus 
statement on the diagnosis of heart failure with normal left ventricu­
lar ejection fraction by the Heart Failure and Echocardiography Asso­
ciations of the European Society of Cardiology. Eur Heart J. 2007; 
28(20):2539–50. 
